TY - JOUR
T1 - Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective
AU - Vriend, Henrike J.
AU - Lugnér, Anna K.
AU - Xiridou, Maria
AU - Schim van der Loeff, Maarten F.
AU - Prins, Maria
AU - de Vries, Henry J. C.
AU - Geerlings, Suzanne E.
AU - Prins, Jan M.
AU - Rijnders, Bart J. A.
AU - van Veen, Maaike G.
AU - Fennema, Johannes S. A.
AU - Postma, Maarten J.
AU - van der Sande, Marianne A. B.
PY - 2013
Y1 - 2013
N2 - To estimate the cost-effectiveness of anorectal chlamydia screening among men who have sex with men (MSM) in care at HIV treatment centers. Transmission model combined with economic analysis over a 20-year period. MSM in care at HIV treatment centers. Once-yearly or twice-yearly screening for anorectal chlamydia among MSM in care at HIV treatment centers. Averted HIV and chlamydia infections; discounted quality-adjusted life-years and costs; incremental cost-effectiveness ratio (ICER). Costs will be saved by routine chlamydia screening of MSM in care at HIV treatment centers if these patients seek little or no screening elsewhere. Nonroutine screening is considerably more expensive than routine screening offered within a scheduled visit. Adding once-yearly chlamydia screening for MSM in care at HIV treatment centers is cost saving when 30% or fewer of those men seek once-yearly screening elsewhere (1.5 to 8.1 million euro saved). Twice-yearly routine screening at HIV treatment centers is cost-effective only when routine screening takes place without additional nonroutine screening (1.9 million euro saved). Adding annual chlamydia screening to the HIV consultation will be cost saving as long as only a limited proportion of men are nonroutinely screened. The ICER was most sensitive to the percentage of MSM that continue to be screened elsewhere
AB - To estimate the cost-effectiveness of anorectal chlamydia screening among men who have sex with men (MSM) in care at HIV treatment centers. Transmission model combined with economic analysis over a 20-year period. MSM in care at HIV treatment centers. Once-yearly or twice-yearly screening for anorectal chlamydia among MSM in care at HIV treatment centers. Averted HIV and chlamydia infections; discounted quality-adjusted life-years and costs; incremental cost-effectiveness ratio (ICER). Costs will be saved by routine chlamydia screening of MSM in care at HIV treatment centers if these patients seek little or no screening elsewhere. Nonroutine screening is considerably more expensive than routine screening offered within a scheduled visit. Adding once-yearly chlamydia screening for MSM in care at HIV treatment centers is cost saving when 30% or fewer of those men seek once-yearly screening elsewhere (1.5 to 8.1 million euro saved). Twice-yearly routine screening at HIV treatment centers is cost-effective only when routine screening takes place without additional nonroutine screening (1.9 million euro saved). Adding annual chlamydia screening to the HIV consultation will be cost saving as long as only a limited proportion of men are nonroutinely screened. The ICER was most sensitive to the percentage of MSM that continue to be screened elsewhere
U2 - https://doi.org/10.1097/QAD.0b013e32836281ee
DO - https://doi.org/10.1097/QAD.0b013e32836281ee
M3 - Article
C2 - 24067620
SN - 0269-9370
VL - 27
SP - 2281
EP - 2290
JO - AIDS (London, England)
JF - AIDS (London, England)
IS - 14
ER -